Quarterly results
We announce our results on a quarterly basis.
This section contains details of our results announcements, to view and download, along with links to related webcasts and presentations. Results from previous years are archived by date, and can be accessed via the filter below.
4 items match your search for '2012'
2012 Fourth Quarter 2012 - released on 6 February 2013
Key points from results
- Core EPS of 112.7p and returns of £6.3bn to shareholders
- 2012 dividend of 74p (+6%)
- Group sales -1%; flat excluding disposals of OTC brands
- Successful R&D delivery: 6 new drugs filed since start of 2012
- Archived analysts’ webcast
Results announcements
2012 Third Quarter 2012 - released on 31 October 2012
Key points from results
- Core EPS of 26.5p
- Dividend of 18p (+ 6%)
- Further successful R&D delivery: phase III programmes completed for 6 novel medicines in 2012
- Continued strong cash generation and returns to shareholders
- Archived analysts' webcast will be available from 1 Nov
Results announcements
2012 Second Quarter 2012 - released on 25 July 2012
Key points from results
- Core EPS of 26.4p
- Dividend of 17p (up 6%)
- Significant late-stage pipeline delivery
- Archived analyst webcast
Results announcements
2012 First Quarter 2012 - released on 25 April 2012
Key points from results
- Sales growth of +2% CER
- Further R&D delivery, operational leverage and continued returns to shareholders
- Core EPS 27.3p (+7%), dividend up 6% to 17p
- Archived analyst webcast
Results announcements